Armstrong Advisory Group’s Edwards Lifesciences EW Stock Holding History

Armstrong Advisory Group’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$137K	Buy	1,518 +508	+50%	+$42.6K	0.01%	310
2026 Q1	$80.9K	Buy	+1,010	New	+$83.3K	0.01%	348
2024 Q3	–	Sell	-42	Closed	-$3.88K	–	804
2024 Q2	$3.88K	Sell	42 -72	-63%	-$6.38K	﹤0.01%	671
2024 Q1	$8.69K	Hold	114	–	–	﹤0.01%	584
2023 Q4	$8.69K	Hold	114	–	–	﹤0.01%	584
2023 Q3	$7.9K	Hold	114	–	–	﹤0.01%	640
2023 Q2	$10.8K	Hold	114	–	–	﹤0.01%	574
2023 Q1	$9.43K	Hold	114	–	–	﹤0.01%	583
2022 Q4	$8.51K	Buy	+114	New	+$8.79K	﹤0.01%	608

Other funds holding EW

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

NONA

Ninety One North America New York $2.13B AUM 9.16% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

SIM

Seilern Investment Management London, United Kingdom $794M AUM 6.63% 1-Year Est. Return

OIAM

OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return

FFM

Fisher Funds Management Auckland, New Zealand $3.52B AUM 17.59% 1-Year Est. Return

Armstrong Advisory Group's EW Position: Q2 2026 in Review

Armstrong Advisory Group increased its Edwards Lifesciences (EW) stake by 50% in Q2 2026, buying an estimated $42.6K and bringing the position to 1,518 shares worth $137K. The position accounts for 0.01% of the portfolio, ranked #310.

Armstrong Advisory Group first reported a position in EW in Q4 2022 and has held it in 9 quarters since. 259 funds tracked by Wall St. Rank hold EW as of Q2 2026.

Armstrong Advisory Group held 1,518 shares of Edwards Lifesciences worth $137K as of Q2 2026.
Armstrong Advisory Group bought 508 Edwards Lifesciences shares in Q2 2026, an estimated $42.6K.
Edwards Lifesciences made up 0.01% of Armstrong Advisory Group's portfolio in Q2 2026, its #310 holding.
Armstrong Advisory Group first reported a position in Edwards Lifesciences in Q4 2022 and has held it in 9 quarters since.
259 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Armstrong Advisory Group's 13F filing for Q2 2026, filed 13 Jul 2026.